+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Nanopharmaceuticals Market by Type (Liposomes, Microemulsion, Nanoemulsion), Application (Anti-Infective, Anti-Inflammatory, Drug Delivery) - Forecast 2024-2030

  • PDF Icon

    Report

  • 183 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4968751
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Nanopharmaceuticals Market size was estimated at USD 102.81 billion in 2023, USD 132.29 billion in 2024, and is expected to grow at a CAGR of 28.76% to reach USD 603.39 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Nanopharmaceuticals Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Nanopharmaceuticals Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Nanopharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca plc, BASF SE, Baxter BioPharma Solutions, Cambrex Corporation, Croda International Plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, Frontage Laboratories, Inc., Johnson & Johnson Services, Inc, Merck & Co., Inc.,, NanoPharmaceuticals LLC, Novartis International AG, Pfizer, Inc., and PharmaCircle, LLC.

Market Segmentation & Coverage

This research report categorizes the Nanopharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Liposomes
    • Microemulsion
    • Nanoemulsion
    • Polymeric Micelles
    • Solid Lipid Nanoparticles
  • Application
    • Anti-Infective
    • Anti-Inflammatory
    • Drug Delivery
    • Neurology
    • Oncology
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Nanopharmaceuticals Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Nanopharmaceuticals Market?
  3. What are the technology trends and regulatory frameworks in the Nanopharmaceuticals Market?
  4. What is the market share of the leading vendors in the Nanopharmaceuticals Market?
  5. Which modes and strategic moves are suitable for entering the Nanopharmaceuticals Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Nanopharmaceuticals Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in the incidence of chronic diseases such as infectious diseases, and cardiovascular diseases
5.1.1.2. High prevalence of neurological disorders and cancer
5.1.1.3. Growing investments to introduce improved medicines
5.1.2. Restraints
5.1.2.1. Lack of regulatory guidelines
5.1.3. Opportunities
5.1.3.1. Huge market potential in pharmaceutical companies for development of effective therapeutics
5.1.3.2. Technological advancements in liposomal drug delivery systems favor development of nanomedicines
5.1.4. Challenges
5.1.4.1. Toxicity issues with nanopharmaceuticals
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Nanopharmaceuticals Market, by Type
6.1. Introduction
6.2. Liposomes
6.3. Microemulsion
6.4. Nanoemulsion
6.5. Polymeric Micelles
6.6. Solid Lipid Nanoparticles
7. Nanopharmaceuticals Market, by Application
7.1. Introduction
7.2. Anti-Infective
7.3. Anti-Inflammatory
7.4. Drug Delivery
7.5. Neurology
7.6. Oncology
8. Americas Nanopharmaceuticals Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Nanopharmaceuticals Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Nanopharmaceuticals Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Abbott Laboratories
12.1.2. AstraZeneca plc
12.1.3. BASF SE
12.1.4. Baxter BioPharma Solutions
12.1.5. Cambrex Corporation
12.1.6. Croda International Plc
12.1.7. Eli Lilly and Company
12.1.8. F. Hoffmann-La Roche AG
12.1.9. Frontage Laboratories, Inc.
12.1.10. Johnson & Johnson Services, Inc
12.1.11. Merck & Co., Inc.,
12.1.12. NanoPharmaceuticals LLC
12.1.13. Novartis International AG
12.1.14. Pfizer, Inc.
12.1.15. PharmaCircle, LLC
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. NANOPHARMACEUTICALS MARKET RESEARCH PROCESS
FIGURE 2. NANOPHARMACEUTICALS MARKET SIZE, 2022 VS 2030
FIGURE 3. NANOPHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. NANOPHARMACEUTICALS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. NANOPHARMACEUTICALS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. NANOPHARMACEUTICALS MARKET DYNAMICS
FIGURE 7. NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 8. NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 10. NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS NANOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 12. AMERICAS NANOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES NANOPHARMACEUTICALS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 14. UNITED STATES NANOPHARMACEUTICALS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC NANOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC NANOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NANOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NANOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. NANOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 20. NANOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. NANOPHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. NANOPHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NANOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. NANOPHARMACEUTICALS MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. NANOPHARMACEUTICALS MARKET SIZE, BY MICROEMULSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. NANOPHARMACEUTICALS MARKET SIZE, BY NANOEMULSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. NANOPHARMACEUTICALS MARKET SIZE, BY POLYMERIC MICELLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. NANOPHARMACEUTICALS MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 12. NANOPHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. NANOPHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. NANOPHARMACEUTICALS MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. NANOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. NANOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS NANOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 22. BRAZIL NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 24. CANADA NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 25. CANADA NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 26. MEXICO NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 27. MEXICO NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES NANOPHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 31. ASIA-PACIFIC NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. ASIA-PACIFIC NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. ASIA-PACIFIC NANOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. AUSTRALIA NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 35. AUSTRALIA NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 36. CHINA NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 37. CHINA NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 38. INDIA NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 39. INDIA NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. INDONESIA NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 41. INDONESIA NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. JAPAN NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 43. JAPAN NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. MALAYSIA NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. MALAYSIA NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. PHILIPPINES NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. PHILIPPINES NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. SINGAPORE NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. SINGAPORE NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. SOUTH KOREA NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 51. SOUTH KOREA NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. TAIWAN NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. TAIWAN NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. THAILAND NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 55. THAILAND NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. VIETNAM NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57. VIETNAM NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA NANOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 61. DENMARK NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. DENMARK NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 63. EGYPT NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. EGYPT NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. FINLAND NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. FINLAND NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. FRANCE NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. FRANCE NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. GERMANY NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. GERMANY NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. ISRAEL NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. ISRAEL NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. ITALY NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. ITALY NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. NETHERLANDS NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. NETHERLANDS NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. NIGERIA NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 78. NIGERIA NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. NORWAY NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. NORWAY NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. POLAND NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. POLAND NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. QATAR NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. QATAR NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. RUSSIA NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. RUSSIA NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. SAUDI ARABIA NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. SAUDI ARABIA NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. SOUTH AFRICA NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. SOUTH AFRICA NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. SPAIN NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. SPAIN NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. SWEDEN NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. SWEDEN NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. SWITZERLAND NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. SWITZERLAND NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. TURKEY NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. TURKEY NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. UNITED ARAB EMIRATES NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. UNITED ARAB EMIRATES NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM NANOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM NANOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. NANOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 104. NANOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 105. NANOPHARMACEUTICALS MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • AstraZeneca plc
  • BASF SE
  • Baxter BioPharma Solutions
  • Cambrex Corporation
  • Croda International Plc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Frontage Laboratories, Inc.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.,
  • NanoPharmaceuticals LLC
  • Novartis International AG
  • Pfizer, Inc.
  • PharmaCircle, LLC

Methodology

Loading
LOADING...

Table Information